RE:RE:The thing is....Because of the past history, I feel that the LoC will be used as a measure of last resort. Also, there is a need to improve market liquidity so an equity raise on Nasdaq would fit the bill. 5M shares at US$ 15- 20 would set the company up very well.
Alternatively, I wouldn’t mind if Lmnl sold a significant interest of its plasma protein business to a private equity firm with cash upfront and under conditions that the new partner finances new iv and sub cutaneous apps before selling the platform 3-4 years from now.